Written Question·Department of Health and Social Care·UIN 62442

Alzheimer's Disease: Donanemab and Lecanemab

Tabled: 24 June 2025

Answered: 1 July 2025

Question

Alex Easton

To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on its decision not to recommend the use of donanemab and lecanemab for Alzheimer's patients by the NHS.

Answer

Karin Smyth

Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including the progress of specific appraisals. NICE develops its guidance independently in line with its established ...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 62442) →